Ra Medical Systems Announces Granting of New US Patent

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) announced the granting of a new patent (number D980,420 S) by the USPTO on March 7, 2023, for its VIVO product's technology. This patent enhances the company's intellectual property portfolio, which now includes 36 issued patents and 15 applications related to electrophysiology products, alongside 15 additional licensed patents for VIVO technology. The VIVO system is a non-invasive 3D imaging solution that helps identify the origins of ventricular arrhythmias, thus improving workflow efficiency and reducing procedure duration. Executive Chairman David Jenkins emphasized the strategic importance of IP for the company’s future value.

Positive

• Issuance of new patent (D980,420 S) strengthens RMED's IP portfolio.
• Total of 36 issued patents and 15 applications for electrophysiology products.
• 15 patents licensed into the company for VIVO technology.
• Enhanced technology for VIVO improves workflow and procedure efficiency.

Negative

• None.

FORT MILL, SC / ACCESSWIRE / March 9, 2022 / Ra Medical Systems, Inc. (NYSE American:RMED) today announced that it has been notified of a new patent granted by the USPTO covering technology utilized in its VIVO product. The patent, number D980,420 S, entitled "Kit of Positioning Patches", was issued on March 7, 2023. The patent covers technology used in the disposable components of the VIVO product.

David Jenkins, Executive Chairman of RMED, commented, "This newly issued patent joins a robust estate of intellectual property accumulated by our company. For the electrophysiology products, we have now have 36 issued patents and 15 application in process. Additionally, we have 15 patents and patent applications licensed into the company covering the VIVO technology. As a small medical device technology company, we believe the obtaining of IP is critical to our future and to the value of our company. We are quite pleased that another US patent has been granted to us."

About VIVO

Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company

David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical

View source version on accesswire.com:
https://www.accesswire.com/742976/Ra-Medical-Systems-Announces-Granting-of-New-US-Patent

FAQ

What is the significance of the new patent awarded to Ra Medical Systems (RMED)?

The new patent (D980,420 S) enhances RMED's intellectual property portfolio, reinforcing the protection of its VIVO product technology.

How many patents does Ra Medical Systems (RMED) currently hold?

Ra Medical Systems currently holds 36 issued patents and has 15 patent applications in process for its electrophysiology products.

What technology does the VIVO product from Ra Medical Systems (RMED) utilize?

The VIVO product uses non-invasive 3D imaging technology to help physicians identify the origins of ventricular arrhythmias.

When was the new patent for Ra Medical Systems (RMED) granted?

The new patent was granted on March 7, 2023.

What impact does the new patent have on Ra Medical Systems (RMED) and its investors?

The new patent protects critical technology, potentially increasing the company's market value and investor confidence.